Fotemustine


Concise Prescribing Info
Indications/Uses
Disseminated malignant melanoma.
Dosage/Direction for Use
Adult : IV Initial: 100 mg/m2/wk for 3 wk to induce remission. Maintenance: Start 4-5 wk after induction course, 100 mg/m2 3 wkly if blood counts permit.
Dosage Details
Intravenous
Disseminated malignant melanoma
Adult: Initially, 100 mg/m2 BSA wkly for 3 wk to induce remission. Maintenance: To be started 4-5 wk after induction course, 100 mg/m2 BSA every 3 wk if blood counts permit. Dose to be given via IV infusion over 1 hr. May also be given intra-arterially.
Contraindications
Pregnancy; lactation; child.
Special Precautions
Elderly, patients with renal or hepatic impairment, recent chemotherapy. Monitor renal, hepatic and lung functions before and during treatment. Monitor blood counts wkly during treatment and for at least 6 wk after last dose; discontinue if granulocyte count is <2000/mm3 or platelet count is <100,000/mm3. Use with caution in patients with reduced lung function.
Adverse Reactions
Bone-marrow suppression and haematological toxicity (possibly delayed); GI disturbances; injection-site phloebitis, fever, pruritus, neurological and biochemical disturbances; transient rise in blood urea; hepatic enzymes and bilirubin elevation.
Drug Interactions
Dacarbazine.
Action
Description: Fotemustine has potent cytostatic anticancer activity on cells in cycle due to its alkylating and carbamoylating effect. It crosses blood brain barrier thus being effective in cerebral and visceral tumors.
Disclaimer: This information is independently developed by MIMS based on Fotemustine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in